Rocket Lab

No trajectory update has cleared publication yet.

• The filing is subject to completion and the merger has not closed. The final stock component depends on Rocket Lab’s price and the stated conditions.
• How many shares, if any, Rocket Lab will ultimately sell under the program and at what prices.
• The amount and timing of cash proceeds actually received, including any forward settlements and commissions.
• Whether the financing will be sufficient to replace the planned bridge facility or change the final acquisition funding mix.
• Whether the proposed Iridium acquisition will close.
• Regulatory approvals, shareholder votes, closing timing, final financing mix, integration costs and realized synergies remain unknown.
• When, or whether, the Form S-4 will become effective.
• Whether the FCC will consent to the proposed transfer of control and on what conditions.
• Whether lenders will approve amendments to Iridium’s term-loan facility.
• The final permanent debt/equity mix, total financing cost and closing date.
• Whether the proposed acquisition will close.
• Closing date, final financing, regulatory approvals, integration costs, and realized synergies are unknown.
• The packet’s 10-Q includes the previously announced Iridium transaction and financing risks, but does not establish closing, final permanent financing, or realized synergies.
• The packet does not establish whether the equity awards correspond exactly to the compensation package described in the 8-K.
• The purpose of Slusky's sale is not stated.
• The packet does not state whether Ricupati's appointment followed a performance issue or other departure-related concern.
• The number of RSUs to be issued is not specified.
• The packet does not provide the aggregate number of shares sold across all reporting persons or aggregate proceeds.
• The packet does not provide the execution-level breakdown for the weighted-average prices beyond the disclosed price ranges.
• The packet does not establish when or at what prices the converted common shares will be sold in future months.
• The packet does not quantify the reporting persons' tax liabilities or the proportion of each reported sale attributable to tax withholding.
• The packet does not provide independent market context or the company's outstanding-share count at the transaction dates.
• Whether the proposed sale was completed and at what prices.
• The seller's post-transaction ownership through Abalone Cove LLLP.
• The terms and timing of the referenced private financings and de-SPAC issuance.
• The filing does not describe the specific future actions that could be affected by removal of the pass-through voting provision.
• No immediate financial effect of the merger is disclosed.
• The filing does not state when the subsidiary merger will become effective.
• How many shares, if any, Rocket Lab will actually sell under the facility.
• The timing and prices of any future sales.
• The net proceeds after commissions and offering expenses.
• Whether Rocket Lab will enter into any forward transactions and, if so, their size, settlement method and timing.
• Which acquisitions or growth initiatives, if any, will receive proceeds.
• The filing does not state how many shares Rocket Lab will ultimately issue or sell.
• No proceeds had been received initially from the described borrowed-share sales.
• The filing does not disclose the company's intended use of proceeds or the timing and size of any actual sales.
• Future settlement method, realized pricing and resulting dilution remain unknown.
• The packet does not confirm whether any resale occurred.
• The packet does not disclose the timing or amount of any future resale.
• The packet does not provide the total consideration paid in the Mynaric acquisition.
• Whether stockholders will approve the proposal at the May 20, 2026 annual meeting.
• Whether the merger will become effective and, if so, the effective date.
• The filing does not quantify the expected costs avoided or financial impact from removing the pass-through voting provision.
• The packet does not provide post-meeting voting results or a subsequent certificate of merger.
• The actual number of shares that will be sold under the plan and the execution prices are unknown.
• The plan's specific temporal, price and volume parameters are not provided in the packet.
• The financial amount of compensation capital redirected to R&D and company priorities is not disclosed.
• The precise dilution impact of cancelling 392,155 RSUs is not quantified.
• Receipts needed next include sale confirmations, subsequent ownership filings, the complete plan terms if disclosed, and company disclosures describing the treatment of the cancelled compensation.
• Whether stockholders will approve the subsidiary merger at the May 20, 2026 annual meeting.
• Whether the merger will be consummated after approval and when the certificate of merger will be filed.
• Which specific future corporate actions may be taken without a parent-stockholder vote after the pass-through provision is removed.
• The final voting results and any subsequent amendments to the merger agreement.
• The amount and timing of any actual common-stock sales.
• The number of shares ultimately issued under agent or forward transactions.
• Whether Rocket Lab elects physical, cash or net-share settlement for any forward transaction.
• The final forward-sale prices, floor prices, cap prices and net proceeds after commissions and other costs.
• The number of shares, if any, that Rocket Lab has sold under the new $1 billion agreement as of the filing date.
• The net proceeds received after commissions, offering expenses and other transaction costs.
• Whether Rocket Lab will enter into any initially priced or collared forward transactions, and the number of shares that would underlie them.
• The timing and size of any future acquisitions or other growth investments funded with proceeds.
• The ultimate dilution to existing shareholders, which will depend on the number and price of shares sold and any forward settlement.
• The packet does not provide the market value of the distributed or remaining shares.
• The packet does not state whether any recipient of the distributions intends to sell shares.
• The filing does not provide a new ownership percentage for the former legacy reporting entities after distribution.
• The extent of the impact on the launch schedule is not yet known.
• The filing does not state whether the tank or other hardware must be redesigned or replaced.
• No cost estimate, revised milestone, or updated launch date is provided.
• The packet does not confirm that the proposed sale occurred or disclose final execution prices, proceeds, or post-sale ownership.
• The packet does not state the percentage of Klein’s total Rocket Lab holdings represented by the proposal.